Author Archives: Antigone Barton

DRC prison TB outbreak brings conditions, risks to wider community, to light

By on .

At a prison where more than one in five inmates was confirmed to be sick with TB, an outbreak investigation sparked recommendations for reforms With a large stock of soon-to-expire Xpert cartridges, at the end of 2014 the diagnostic laboratory near the Democratic Republic of Congo’s Mbuji-Mayi medium security prison started using the technology for […]

WHO emergency committee: DRC Ebola outbreak “extraordinary” but not a PHEIC

By on .

While security concerns stemming from ongoing local armed conflict pose extraordinary challenges, and proximity to neighboring countries raise risks of cross border spread, the current outbreak of Ebola in the Democratic Republic of Congo does not meet the criteria to be declared a Public Health Emergency of International Concern — or PHEIC — a committee […]

Citing overlooked social, economic, health impacts, study estimates West Africa Ebola outbreak costs at more than $53 billion

By on .

Estimate exceeds previous estimates by more than $20 billion Deaths from non-Ebola causes contributed to highest West Africa outbreak costs, authors say During the 2013 to 2016 spread of Ebola across Guinea, Liberia and Sierra Leone, as health systems and health workers were overtaken by the impacts of the virus, about a million fewer children […]

Site provides global view of outbreak preparedness

By on .

In July 2018, the arrival in Lagos, Nigeria of a man sick with Ebola represented a pivotal moment in the crisis that already was ravaging families, communities, health systems and economies across Sierra Leone, Guinea and Liberia. The outbreak of the virus, which had started the previous December, unnoticed by the larger world with the […]

What we’re reading: How to make the most of science, save lives, stop the spread of diseases

By on .

What you need to know about South Africa’s historic liver transplant from an HIV-positive donor – Five years after the HOPE Act in the U.S. opened the way for people living with HIV to be organ donors, and increased the chances that people living with the virus would receive life-saving transplants, physicians in South Africa […]

Fighting TB starts with data

By on .

The following is a guest post by Stephanie Mullen, DrPH, and Jim Thomas, PhD of MEASURE Evaluation USAID announced September 26 a new approach to fight tuberculosis: the Global Accelerator to End TB, a business model to treat 40 million people by 2022 through performance-based investments. One of USAID’s initial efforts on this front is […]

Bangladesh, USAID DR TB treatment project shows impacts of community-based approach

By on .

A project that shifted treatment for drug-resistant tuberculosis from overburdened Bangladesh hospitals to patients’ homes saw time between diagnosis and treatment initiation drop from more than three months to less than a week, reducing risks of the continued spread of the disease, a study reported in Global Health Science and Practice found. In the process, researchers […]

WHO 2018 global TB report presented as agenda for UN meeting, commitments

By on .

In 2017, around the world as many as 4,000 people died of tuberculosis on any given day. That added up to an estimated — give or take several hundred thousand lives — 1.3 million people killed by a curable disease. An estimated 10 million people developed tuberculosis — a disease that also is preventable. The […]

Guide gives direction to the last 90

By on .

The following is a guest post By Sharon Weir, Ph.D. of MEASURE Evaluation For almost 35 years, HIV/AIDS has been a household word across the globe. At first a death sentence, HIV has infected 78 million people, killing almost half of them as the world battled it into submission as a treatable, chronic—but still dangerous—condition. […]

Dolutegravir results in low-resource setting highlight benefits

By on .

A standard of care treatment in high-income settings, the benefits of dolutegravir-based treatments for HIV have been clear, with a built-in barrier to the development of drug-resistance, and a less frequent or severe side effects that interfere with staying on a medicine. But the benefits in low-income countries have been harder to assess, with costs, […]